OptiBiotix, a developer of human microbiome modulators, has signed a manufacturing and supply agreement with SACCO to market its cholesterol-reducing probiotic strain LP LDL to the more than 2,500 food, beverage, consumer healthcare, and pharmaceutical companies it serves across Europe.
LP LDL is an ingredient that has been shown in double blind placebo controlled trials to lower cholesterol and blood pressure and when combined with a prebiotic can increase the production and function of a specific bacterium in the microbiome. LP LDL will be supplied by Sacco as a raw ingredient to food, beverage, consumer healthcare, and pharmaceutical partners to be incorporated into a wide range of final formulations and presentations.
The agreement grants SACCO, a probiotic manufacturer and raw material supplier in Europe, an exclusive license to manufacture, market, and supply ingredients in Europe.
OptiBiotix is in discussions with other partners in the United States, Asia, and other international markets.
“I believe we are fast approaching the next stage in the development of the microbiome in healthcare, where scientists will have the ability to precision engineer components of the microbiome to prevent, manage, and treat many of today’s chronic lifestyle diseases,” said Stephen O’Hara, CEO of OptiBiotix. “OptiBiotix will continue to be at the forefront of global microbiome research and the development of new products.”